Five-Years After PFO Closure: Procedural Safety and Effectiveness

Five-year outcomes of the randomized REDUCE study showed a continuous benefit from patent foramen ovale (PFO) closure compared with antiplatelet agents to prevent cryptogenic strokes.

5 años del cierre del FOP

The most important aspect of this result seems to be the idea that PFO closure in selected patients offers durable benefit with guaranteed long-term safety.

The original results from REDUCE were presented at the European Stroke Organization Conference in 2017. There, the study demonstrated a 77% recurrent ischemic stroke risk reduction with PFO closure vs. antiplatelet therapy at about 3.2 years of follow-up.

The results presented now in NEJM show that the benefit from this intervention is sustained to prevent recurrent stroke at 5-years of follow-up (1.8% vs. 5.4%; hazard ratio: 0.31; 95% confidence interval: 0.13 to 0.76). In absolute terms, the advantage is 3.6%; therefore, 25 PFO closures are needed to prevent a stroke.

Other safety endpoints like death, major bleeding, and deep venous thrombosis were similar between groups without any further complications related to the device.


Read also: Major Cause of Myocardial Injury by COVID-19.


The only difference against the closing device was a higher risk of atrial fibrillation (6.8% vs. 0.4%). These data require further follow-up, as the increased chances of atrial fibrillation could dilute the benefit in terms of stroke and the increased need for anticoagulation could modify bleeding rates against the device.

Investigators from the REDUCE trial are collaborating with investigators from other large studies on the topic (RESPECT, CLOSE, CLOSURE I, PF, DEFENSE PFO) to produce a large meta-analysis that will shed light on predictors of atrial fibrillation, late stroke, and other complications.

Conclusion

The foramen ovale closure device maintained its superiority in preventing recurrent strokes vs. medical treatment at 5 years of follow-up in patients with cryptogenic stroke and patent foramen ovale.

nejmc2033779

Original Title: Five-year outcomes of PFO closure or antiplatelet therapy for cryptogenic stroke.

Reference: Kasner SE et al. N Engl J Med. 2021;384:970-971.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...